The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.
An interdisciplinary European group of clinical experts in the field of movement disorders and experienced Botulinum toxin users has updated the consensus for the use of Botulinum toxin in the treatment of children with cerebral palsy (CP). A problem-orientated approach was used focussing on both published and practice-based evidence. In part I of the consensus the authors have tabulated the supporting evidence to produce a concise but comprehensive information base, pooling data and experience from 36 institutions in 9 European countries which involves more than 10,000 patients and over 45,000 treatment sessions during a period of more than 280 treatment years. In part II of the consensus the Gross Motor Function Measure (GMFM) and Gross Motor Function Classification System (GMFCS) based Motor Development Curves have been expanded to provide a graphical framework on how to treat the motor disorders in children with CP. This graph is named "CP(Graph) Treatment Modalities - Gross Motor Function" and is intended to facilitate communication between parents, therapists and medical doctors concerning (1) achievable motor function, (2) realistic goal-setting and (3) treatment perspectives for children with CP. The updated European consensus 2009 summarises the current understanding regarding an integrated, multidisciplinary treatment approach using Botulinum toxin for the treatment of children with CP.
Heinen
Florian
F
Department of Paediatric Neurology and Developmental Medicine, Dr. von Hauner's Children's Hospital, University of Munich, Lindwurmstr. 4, 80337 Munich, Germany.
Desloovere
Kaat
K
Schroeder
A Sebastian
AS
Berweck
Steffen
S
Borggraefe
Ingo
I
van Campenhout
Anya
A
Andersen
Guro L
GL
Aydin
Resa
R
Becher
Jules G
JG
Bernert
Günther
G
Caballero
Ignacio Martinez
IM
Carr
Lucinda
L
Valayer
Emmanuelle Chaleat
EC
Desiato
Maria Teresa
MT
Fairhurst
Charlie
C
Filipetti
Paul
P
Hassink
Ralph-Ingo
RI
Hustedt
Ulf
U
Jozwiak
Marek
M
Kocer
Serdar Ibrahim
SI
Kolanowski
Elisabeth
E
Krägeloh-Mann
Ingeborg
I
Kutlay
Sehim
S
Mäenpää
Helena
H
Mall
Volker
V
McArthur
Paul
P
Morel
Edith
E
Papavassiliou
Antigone
A
Pascual-Pascual
Ignacio
I
Pedersen
Søren Anker
SA
Plasschaert
Frank S
FS
van der Ploeg
Irene
I
Remy-Neris
Olivier
O
Renders
Anne
A
Di Rosa
Guiseppe
G
Steinlin
Maja
M
Tedroff
Kristina
K
Valls
Joan Vidal
JV
Viehweger
Elke
E
Molenaers
Guy
G
D018726:Anti-Dyskinesia Agents / Q000592:standards / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000592:standards / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy*; D005060:Europe / Q000453:epidemiology; D006801:Humans; D010372:Pediatrics
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins